EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)
Medtronic Vascular, Inc. · Decision date Mar 7, 2012
What did the FDA approve?
FDA records show approval of the EverFlex Self-Expanding Peripheral Stent System, not a separate supplement or a broader re-approval of a different device. The source statement names the device and gives its stated purpose, but it does not describe clinical outcomes, testing results, or any change to prior PMA scope beyond the approval entry itself.
The recorded intended use is narrow and technical: to improve luminal diameter for symptomatic de novo or restenotic lesions up to 180 mm in the native superficial femoral artery and/or proximal popliteal arteries, with reference vessel diameters of 4.5 to 7.5 mm. No other indication, patient selection detail, or performance claim is supplied in the provided text.
FDA approval order statement
APPROVAL FOR THE EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM. THIS DEVICE IS INTENDED TO IMPROVE LUMINAL DIAMETER IN THE TREATMENT OF SYMPTOMATIC DE NOVO OR RESTENOTIC LESIONS UP TO 180MM IN LENGTH IN THE NATIVE SUPERFICIAL FEMORAL ARTERY (SFA) AND/OR PROXIMAL POPLITEAL ARTERIES WITH REFERENCE VESSEL DIAMETERS RANGING FROM 4.5 -7.5MM.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 7, 2012
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110023
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIP
- Decision code
- APPR
- Decision date
- Mar 7, 2012
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- NIP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P110023 received
Application receipt date recorded by FDA.
P110023 · FDA decision
APPR
P110023/S069 · Related supplement
EverFlex Self-Expanding Peripheral Stent System; EverFlex Self-Expanding Peripheral Stent with Entrust Delivery Syste
P110023/S070 · Related supplement
EVERFLEX SELF-EXPANDING PERIPHERAL STENT SYSTEM (EVERFLEX)
Timeline entries are records held by MedtechLedger for P110023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA | |
| Abbott Vascular (Idef Technologies Inc) | PMA approval | Mar 28, 2014 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P110023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



